G1 Phase Calculators

0 calculators tagged with “G1 Phase”

G1 (Gap 1) phase is the first growth phase of the cell cycle, occurring between mitosis (M phase) and DNA synthesis (S phase). During G1, cells grow in size, synthesize proteins and organelles, and integrate internal and external signals to determine whether to commit to another round of division. The critical decision point is the restriction point (Start in yeast) — a point in late G1 beyond which the cell is committed to completing division regardless of extracellular signals. G1 progression is driven by cyclin D-CDK4/6 complexes, which phosphorylate and inactivate the retinoblastoma protein (Rb), releasing E2F transcription factors to drive S-phase gene expression.

All Calculators

No calculators found for this topic.

Cell Cycle Overview

G1 → S → G2 → M (mitosis) → G1. Interphase = G1 + S + G2. G0 = quiescent state (cells exit cell cycle; no division). Duration: G1 is the most variable phase (hours to days depending on cell type and signals); S = ~8h; G2 = ~4h; M = ~1h. Total cell cycle: mammalian cells ~24h in culture.

What Happens in G1

  • Cell growth (protein synthesis, organelle biogenesis)
  • Assessment of external signals: growth factors (EGF, PDGF, FGF), mitogen signaling via Ras/MAPK pathway
  • Assessment of nutrient and energy status (mTOR pathway)
  • DNA damage checkpoint: if DNA damaged → p53 activates p21 (CKI) → CDK2 inhibition → G1 arrest → time for repair or apoptosis
  • Late G1: commitment at the restriction point

Rb/E2F Pathway (Restriction Point Mechanism)

Early G1: Rb is unphosphorylated → binds E2F transcription factors → represses S-phase genes. Mitogenic signals → cyclin D expression → CDK4/6 activation → Rb phosphorylation → E2F released → S-phase gene expression (cyclin E, E2F targets). Once Rb is hyperphosphorylated: positive feedback from cyclin E-CDK2 → Rb remains off → cell commits to S phase (restriction point passed).

Cancer Relevance

The Rb pathway is disrupted in ~>90% of human cancers: Rb mutation (retinoblastoma, many tumors); CDK4/6 amplification; cyclin D overexpression; loss of CDK inhibitors (p16/INK4a). CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) restore G1 arrest in Rb-proficient breast cancer.

Glossary

G1 Phase
The first growth phase of the cell cycle (between M and S phases); cell grows, synthesizes proteins, integrates growth signals; contains the restriction point beyond which division is committed.
Restriction Point
A late G1 checkpoint beyond which cells are committed to completing division; defined by irreversible Rb hyperphosphorylation and E2F release; lost in most cancers, causing growth-factor-independent proliferation.
CDK4/6 Inhibitors
Drugs (palbociclib, ribociclib, abemaciclib) that block cyclin D-CDK4/6 → prevent Rb phosphorylation → G1 arrest; approved for HR+/HER2− breast cancer; require functional Rb for efficacy.

Frequently Asked Questions

G1 (Gap 1) is the first phase of the cell cycle, occurring after mitosis and before DNA replication (S phase). It is the primary period of cell growth and preparation for division: Cell growth: cells double in size; ribosomes, mitochondria, and other organelles are synthesized; proteins needed for DNA replication are stockpiled. Signal integration: cells assess whether conditions favor division (growth factor availability, nutrient and energy status, cell-cell contact, extracellular matrix signals). DNA damage assessment: if DNA damage is detected, the G1 checkpoint arrests the cell via p53→p21→CDK inhibition. G1 is the most variable phase — its duration is controlled by the balance of pro-proliferative signals (growth factors, cyclins) and anti-proliferative signals (CDK inhibitors, growth arrest signals).

The restriction point (R-point, or 'Start' in yeast) is a point in late G1 beyond which cells are committed to completing cell division, regardless of external mitogenic signals. Before R-point: cells need continuous growth factor stimulation to proceed with division; withdrawal leads to G1 arrest or G0. After R-point: cells complete the cell cycle autonomously even if growth factors are removed. Molecular basis: the R-point corresponds to the irreversible hyperphosphorylation of Rb (retinoblastoma protein) by cyclin E-CDK2 in a positive feedback loop. Once Rb is fully inactivated, E2F transcription factors are permanently released → S-phase gene expression is irreversible. Cancer significance: most cancer cells have lost R-point control — they proliferate without growth factor stimulation because Rb or its regulators are mutated.

Rb (retinoblastoma protein) is the key G1 checkpoint regulator: Early G1 (Rb active): unphosphorylated Rb binds E2F transcription factors → represses E2F target genes (cyclin E, DHFR, E2F itself) → cells stay in G1 or G0. Mitogenic signal → cyclin D synthesis → CDK4/6-cyclin D phosphorylates Rb on specific sites → partial Rb inactivation → some E2F release → cyclin E expression. Cyclin E-CDK2 further phosphorylates Rb → hyperphosphorylation → complete Rb inactivation → all E2F targets expressed → S-phase entry. Positive feedback: cyclin E-CDK2 further activates E2F → more cyclin E → more CDK2 activity → bistable switch → irreversible commitment past R-point.

CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) block cyclin D-CDK4/6 kinase complexes → prevent Rb phosphorylation → Rb remains active → E2F remains repressed → cells arrested in G1 → cannot replicate DNA. Approved use: hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (combined with aromatase inhibitors or fulvestrant); double progression-free survival vs. endocrine therapy alone. Requirement: functional Rb protein (if Rb is mutated/deleted, CDK4/6 inhibition cannot arrest cells — Rb mutation = resistance). Mechanism of sensitivity: HR+ breast cancer frequently has cyclin D1 amplification or CDK4/6 overactivation → particularly dependent on the CDK4/6-Rb pathway → highly sensitive to CDK4/6 inhibitors.